# Kiora Pharmaceuticals Inc: Form 10-Q for the period ended Jun 30, 2018

- Company: [Kiora Pharmaceuticals Inc](/companies/kprx.md) (CIK 1372514)
- Form: 10-Q
- Filed: 2018-08-03
- Accepted by EDGAR: Aug 3, 2018, 08:32 ET
- Period: 2018-06-30
- Accession: 0001144204-18-041798
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1372514/000114420418041798/tv499549_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1372514/000114420418041798/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2018-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2018-04-01 to 2018-06-30 | $242.0k | us-gaap:Revenues |
| Revenue | 6 months, 2018-01-01 to 2018-06-30 | $1.3m | us-gaap:Revenues |
| Research and development | 3 months, 2018-04-01 to 2018-06-30 | $1.8m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2018-01-01 to 2018-06-30 | $4.4m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2018-04-01 to 2018-06-30 | −$2.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2018-01-01 to 2018-06-30 | −$5.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2018-04-01 to 2018-06-30 | $304 | us-gaap:InterestExpense |
| Interest expense | 6 months, 2018-01-01 to 2018-06-30 | $608 | us-gaap:InterestExpense |
| Net income | 3 months, 2018-04-01 to 2018-06-30 | −$2.8m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2018-01-01 to 2018-06-30 | −$5.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2018-04-01 to 2018-06-30 | −$0.07 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months, 2018-01-01 to 2018-06-30 | −$0.19 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months, 2018-01-01 to 2018-06-30 | −$6.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | at 2018-06-30 | $12.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2018-06-30 | $13.2m | us-gaap:AssetsCurrent |
| Total assets | at 2018-06-30 | $19.1m | us-gaap:Assets |
| Current liabilities | at 2018-06-30 | $4.1m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2018-06-30 | $5.5m | us-gaap:Liabilities |
| Shareholders' equity | at 2018-06-30 | $13.5m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1372514/000114420418041798/tv499549_10q.htm

Filed Aug 3, 2018.
Source: SEC EDGAR, the filing index for accession 0001144204-18-041798. Last ingested by Listed: Nov 12, 2026, 17:43 ET. No prices; not investment advice.
